A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 pa...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology Vol. 146; no. 2; pp. 171 - 179
Main Authors: Forero‐Torres, Andres, Leonard, John P., Younes, Anas, Rosenblatt, Joseph D., Brice, Pauline, Bartlett, Nancy L., Bosly, Andre, Pinter‐Brown, Lauren, Kennedy, Dana, Sievers, Eric L., Gopal, Ajay K.
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01.07.2009
Blackwell
Subjects:
Adult
Aged
anaplastic large cell lymphoma
anaplastic lymphoma kinase
Antibodies, Anti-Idiotypic - blood
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antineoplastic Agents - administration & dosage
anti‐CD30 antibody
Biological and medical sciences
Chimerin Proteins - blood
Dose-Response Relationship, Drug
Female
Hematologic and hematopoietic diseases
Hodgkin Disease - therapy
Hodgkin lymphoma
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Large-Cell, Anaplastic - drug therapy
Male
Medical sciences
Middle Aged
monoclonal antibody
Young Adult
Hematology
anti-CD30 antibody
Anaplastic cell lymphoma
Hodgkin disease
Malignant hemopathy
Large cell lymphoma
Monoclonal antibody
Non Hodgkin lymphoma
Treatment
Lymphoproliferative syndrome
Phase II trial
anaplastic large cell lymphoma
Anaplastic lymphoma kinase
Cancer
Hodgkin lymphoma
ISSN:0007-1048, 1365-2141, 1365-2141
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN‐30 comprised 6 weekly intravenous infusions, followed by a 2‐week treatment‐free period. Patients had received a median of 3 (range 1–5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62–242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN‐30 is safe, with modest clinical activity in patients with ALCL.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0007-1048
1365-2141
1365-2141
DOI:10.1111/j.1365-2141.2009.07740.x